Welcome to our dedicated page for Vyne Therapeutics news (Ticker: VYNE), a resource for investors and traders seeking the latest updates and insights on Vyne Therapeutics stock.
VYNE Therapeutics Inc. develops differentiated therapies for chronic inflammatory and immune-mediated conditions through proprietary BET inhibitor programs. News about VYNE centers on its InhiBET™ platform, Repibresib gel for nonsegmental vitiligo, and VYN202, an oral BD2-selective BET inhibitor being evaluated for immune-mediated diseases.
Company updates also cover clinical and regulatory communications, nonclinical toxicology work, quarterly operating results, cost-control actions, capital-structure matters, governance developments, and shareholder voting matters tied to its Nasdaq-listed common stock.
VYNE Therapeutics (Nasdaq: VYNE) has distributed its previously announced special cash dividend on July 23, 2026 to stockholders of record as of July 22, 2026, with entitlement governed by Nasdaq’s due bill procedures during the July 21–23 due bill period.
VYNE’s 1-for-50 reverse stock split is expected on July 24, 2026, with post-split trading on Nasdaq beginning July 27, 2026 under CUSIP 92941V407 and ISIN US92941V4077. The proposed merger with Yarrow Bioscience, previously expected to close around July 24, is now expected to close early in the week of July 27, 2026, subject to final Nasdaq approval of the combined company’s listing. After closing, the combined company’s common stock is expected to trade on Nasdaq as “Yarrow Bioscience, Inc.” under ticker “YARW”. The cash dividend exceeds 25% of VYNE’s stock price on the declaration date, resulting in a July 24, 2026 ex-dividend date.
VYNE Therapeutics (Nasdaq: VYNE) approved a 1-for-50 reverse stock split of its common stock in connection with the anticipated merger with Yarrow Bioscience. The split, already approved by stockholders, is expected to reduce outstanding shares from approximately 33.4 million to about 0.7 million, without changing authorized shares.
Following the merger, the combined company is expected to trade on Nasdaq as “Yarrow Bioscience” under ticker YARW starting July 27, 2026. VYNE stockholders also will receive an aggregate special cash dividend of $17.3 million, or about $0.40242 per share, payable to stockholders and warrant holders of record as of July 22, 2026, with payment expected on July 23, 2026.
Due bill procedures will apply from July 21 through the payment date, so investors must hold shares through the payment date to receive the dividend. After the reverse split and merger closing, total issued and outstanding common stock of the combined company is expected to be about 2.7 million basic shares, or 33.6 million on a fully diluted basis.
VYNE Therapeutics (Nasdaq: VYNE) declared a special cash dividend estimated at an aggregate $16.5 million, or approximately $0.38 per share, in connection with its proposed merger with Yarrow Bioscience under the December 17, 2025 Merger Agreement.
The dividend will be payable in cash to stockholders and warrant holders of record as of July 22, 2026. The estimate is based on VYNE’s calculation of net cash in excess of $0 prior to closing and on 42,989,506 common shares and equivalents outstanding as of July 9, 2026. The actual amount, to be funded to the transfer agent on July 23, 2026, may be higher or lower than the estimate.
Payment of the dividend is conditioned on closing of the merger, which is expected on or about July 24, 2026, subject to stockholder approval and other conditions. VYNE’s special stockholder meeting to vote on the merger is scheduled for July 16, 2026 at 10:00 a.m. Eastern Time.
VYNE Therapeutics (Nasdaq: VYNE) and Yarrow Bioscience entered a definitive all-stock merger; the combined company expects to operate as Yarrow Bioscience and trade on Nasdaq as YARW.
A syndicate led by RTW Investments committed to pre-closing financings of approximately $200.0 million, and the combined company’s cash at closing is expected to fund operations into 2028. VYNE expects to declare a pre-closing cash dividend of about $14.5–$16.5 million to pre-merger VYNE stockholders.
The combined company will advance Yarrow’s lead program, YB-101 (GS-098), into a U.S.-based Phase 1b/2b trial in H1 2026 with Phase 1b data expected in H2 2027; a Phase 1 TED trial is ongoing in China via partner GenSci.
VYNE (Nasdaq: VYNE) reported third quarter 2025 results and a business update on Nov 6, 2025. The company has $32.7 million in cash and believes this will fund operations into the first half of 2027. VYNE’s Board initiated a strategic review in August 2025 to evaluate partnerships, licensing, M&A, asset sales or other alternatives; LifeSci Capital was engaged as financial advisor.
Clinical programs: a 12-week repeat non‑clinical toxicology study in dogs for VYN202 is underway to address a partial FDA hold for male subjects; repibresib gel Phase 2b missed primary and secondary endpoints and the extension phase is being terminated. Q3 results: net loss $7.3M ($0.17/share); R&D down 48.7% YoY to $5.3M.
VYNE Therapeutics (Nasdaq: VYNE) reported Q2 2025 financial results and provided updates on its pipeline programs. The company ended Q2 with $39.6 million in cash, extending runway into first half of 2027. Net loss improved to $5.8 million ($0.13 per share) compared to $9.4 million ($0.22 per share) in Q2 2024.
Key developments include promising efficacy signals for VYN202, their oral BD2-selective BET inhibitor, in psoriasis and other conditions. The FDA partially lifted a clinical hold on VYN202, allowing female enrollment while requiring additional toxicology data for male subjects. Their topical BET inhibitor, repibresib, missed primary endpoints in Phase 2b vitiligo trial, leading to trial termination. The company is now seeking a development partner for repibresib.
VYNE Therapeutics (Nasdaq: VYNE) reported disappointing topline results from its Phase 2b trial of Repibresib gel for nonsegmental vitiligo. The trial, involving 177 subjects, failed to meet its primary endpoint of F-VASI50 and key secondary endpoint of F-VASI75 at week 24 compared to vehicle.
Despite missing main endpoints, the 3% concentration showed nominally significant effects in secondary endpoints: -43.6% change from baseline in F-VASI score (vs. -25.6% vehicle) and -28.3% in T-VASI score (vs. -16.2% vehicle). Results were impacted by an unusually high vehicle effect and higher dropout rates in active arms (36.6% for 3% concentration vs. 10.6% for vehicle).
The company will terminate the trial's extension phase and seek an external partner for Repibresib's continued development. VYNE reported approximately $39.6 million in cash and equivalents as of June 30, 2025.
VYNE Therapeutics (Nasdaq: VYNE) provided an update on its VYN202 program following an FDA clinical hold in April. The FDA has partially lifted the hold, allowing female patients to receive 0.25 mg and 0.5 mg doses in the Phase 1b psoriasis trial. The hold was initially placed due to testicular toxicity observed in dogs during non-clinical studies.
Preliminary data from the small trial (n=7) showed promising results: PASI score improvements ranged from 27% reduction after 1 week to 90% reduction at week 8. Significant reductions in key inflammatory biomarkers were observed, and a patient with psoriatic arthritis showed meaningful improvement in joint pain. The company will discontinue enrollment in the Phase 1b psoriasis study, extending its cash runway into Q4 2026.
VYNE Therapeutics (Nasdaq: VYNE) announced that the FDA has placed a clinical hold on its Phase 1b study of VYN202 for moderate-to-severe plaque psoriasis treatment. The hold follows the discovery of testicular toxicity in dogs during non-clinical toxicology studies.
The company has suspended all screening, enrollment, and patient dosing for the VYN202 trial. While no serious adverse events have been reported in enrolled subjects, VYNE will work with the FDA to resolve the clinical hold.
Importantly, the clinical hold does not affect VYNE's ongoing Phase 2b trial of repibresib gel in nonsegmental vitiligo, which is a distinct compound from VYN202. Top-line results from the 24-week double-blind, vehicle-controlled portion of this trial are expected mid-year.